JP2019510741A5 - - Google Patents

Download PDF

Info

Publication number
JP2019510741A5
JP2019510741A5 JP2018540718A JP2018540718A JP2019510741A5 JP 2019510741 A5 JP2019510741 A5 JP 2019510741A5 JP 2018540718 A JP2018540718 A JP 2018540718A JP 2018540718 A JP2018540718 A JP 2018540718A JP 2019510741 A5 JP2019510741 A5 JP 2019510741A5
Authority
JP
Japan
Prior art keywords
buffer
cytotoxic agent
ala
val
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018540718A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019510741A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/016344 external-priority patent/WO2017136623A1/en
Publication of JP2019510741A publication Critical patent/JP2019510741A/ja
Publication of JP2019510741A5 publication Critical patent/JP2019510741A5/ja
Pending legal-status Critical Current

Links

JP2018540718A 2016-02-05 2017-02-03 細胞結合剤・細胞毒性剤コンジュゲートを調製するための効率的なプロセス Pending JP2019510741A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662292018P 2016-02-05 2016-02-05
US62/292,018 2016-02-05
PCT/US2017/016344 WO2017136623A1 (en) 2016-02-05 2017-02-03 Efficient process for preparing cell-binding agent-cytotoxic agent conjugates

Publications (2)

Publication Number Publication Date
JP2019510741A JP2019510741A (ja) 2019-04-18
JP2019510741A5 true JP2019510741A5 (https=) 2020-03-12

Family

ID=58159509

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018540718A Pending JP2019510741A (ja) 2016-02-05 2017-02-03 細胞結合剤・細胞毒性剤コンジュゲートを調製するための効率的なプロセス

Country Status (12)

Country Link
US (1) US20210299265A1 (https=)
EP (1) EP3411077A1 (https=)
JP (1) JP2019510741A (https=)
KR (1) KR20180105233A (https=)
CN (1) CN108601848A (https=)
AU (1) AU2017213858A1 (https=)
CA (1) CA3013125A1 (https=)
MA (1) MA47022A (https=)
RU (1) RU2018130108A (https=)
SG (1) SG11201806478PA (https=)
TW (1) TW201731532A (https=)
WO (1) WO2017136623A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3220959A1 (en) * 2014-11-19 2017-09-27 ImmunoGen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
KR20240000650A (ko) 2016-10-19 2024-01-02 인벤라 인코포레이티드 항체 구조물
EP3559039A1 (en) 2016-12-22 2019-10-30 Università Degli Studi Magna Graecia Catanzaro A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43
WO2019234136A1 (en) 2018-06-05 2019-12-12 King's College London Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system
SG11202012257VA (en) * 2018-06-26 2021-01-28 Immunogen Inc Immunoconjugates targeting adam9 and methods of use thereof
KR102284800B1 (ko) * 2020-12-30 2021-08-03 주식회사 하플사이언스 재조합 세포외 기질 단백질의 생산을 위한 동물세포 배양용 배지 조성물 및 이를 이용한 방법

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
SE9102074D0 (sv) 1991-07-03 1991-07-03 Kabi Pharmacia Ab Tomour antigen specific antibody
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
ES2149768T3 (es) 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
IL111748A0 (en) 1993-12-03 1995-01-24 Zeneca Ltd Proteins
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5958872A (en) 1996-04-01 1999-09-28 Apoptosis Technology, Inc. Active survival domains of IGF-IR and methods of use
CA2297070A1 (en) 1997-08-01 1999-02-11 Morphosys Ag Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex
TW593241B (en) 1999-04-20 2004-06-21 Hoffmann La Roche Carbamic acid derivatives
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
US6596503B1 (en) 2000-08-18 2003-07-22 East Carolina University Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
BRPI0116728B1 (pt) 2001-01-05 2018-10-30 Pfizer Inc. anticorpos para receptor de fator de crescimento i semelhante à insulina
BR0316101A (pt) 2002-11-07 2005-09-27 Immunogen Inc Anticorpos anticd33 e processo para tratamento de leucemia melóide aguda usando os mesmos
CN102558352A (zh) 2003-06-27 2012-07-11 艾默根佛蒙特有限公司 针对表皮生长因子受体的缺失突变体的抗体及其使用
KR20120064120A (ko) 2004-06-01 2012-06-18 제넨테크, 인크. 항체 약물 접합체 및 방법
CA2486285C (en) 2004-08-30 2017-03-07 Viktor S. Goldmakher Immunoconjugates targeting syndecan-1 expressing cells and use thereof
EP1817341A2 (en) 2004-11-29 2007-08-15 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
PL1819359T3 (pl) 2004-12-09 2015-08-31 Janssen Biotech Inc Immunokoniugaty skierowane przeciw integrynie, metody ich wytwarzania oraz ich zastosowanie
CA2600929A1 (en) 2005-03-04 2006-09-14 Biogen Idec Ma Inc. Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
JP5861223B2 (ja) 2009-02-23 2016-02-16 サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. プロタンパク質およびその使用方法
AR076284A1 (es) 2009-04-29 2011-06-01 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
AR078471A1 (es) 2009-10-02 2011-11-09 Sanofi Aventis COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS
TW201116297A (en) 2009-10-02 2011-05-16 Sanofi Aventis Antibodies that specifically bind to the EphA2 receptor
CN103037900B (zh) 2010-02-24 2016-04-06 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
SG183542A1 (en) 2010-03-12 2012-10-30 Immunogen Inc Cd37-binding molecules and immunoconjugates thereof
WO2012019024A2 (en) 2010-08-04 2012-02-09 Immunogen, Inc. Her3-binding molecules and immunoconjugates thereof
CN103269712B (zh) 2010-11-03 2016-09-21 伊缪诺金公司 包含新型安丝菌素衍生物的细胞毒性剂
US9260483B2 (en) 2011-01-10 2016-02-16 Technische Universität München Triazacyclononane-based phosphinate ligand and its use for molecular imaging
JP6049642B2 (ja) * 2011-02-15 2016-12-21 イミュノジェン・インコーポレーテッド 複合体の調製方法
RS58367B1 (sr) * 2011-03-29 2019-03-29 Immunogen Inc Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
CN103648532A (zh) * 2011-06-21 2014-03-19 伊缪诺金公司 具有肽连接子的新型美登木素生物碱衍生物及其偶联物
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates

Similar Documents

Publication Publication Date Title
JP2019510741A5 (https=)
RU2018130108A (ru) Эффективный способ получения конъюгатов связывающийся с клеткой агент цитотоксический агент
Zhao et al. Synthesis and evaluation of hydrophilic linkers for antibody–maytansinoid conjugates
Park et al. Enhanced BBB permeability of osmotically active poly (mannitol-co-PEI) modified with rabies virus glycoprotein via selective stimulation of caveolar endocytosis for RNAi therapeutics in Alzheimer's disease
US10981914B2 (en) Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
AU2015273098B2 (en) Auristatin derivatives and conjugates thereof
Dorywalska et al. Effect of attachment site on stability of cleavable antibody drug conjugates
DeVay et al. Improved lysosomal trafficking can modulate the potency of antibody drug conjugates
JP3222461B2 (ja) 新規タンパク質―ポリカチオン結合体
JP2024542073A (ja) 抗体薬物結合体のための特異的共役
ES2788864T3 (es) Conjugados de anticuerpo-fármaco e inmunotoxinas
Tong et al. Conjugates of superoxide dismutase 1 with amphiphilic poly (2-oxazoline) block copolymers for enhanced brain delivery: synthesis, characterization and evaluation in vitro and in vivo
Salomon et al. Optimizing lysosomal activation of antibody–drug conjugates (ADCs) by incorporation of novel cleavable dipeptide linkers
CN109689111B (zh) 吡咯并苯并二氮杂䓬前药及其抗体缀合物
JP2018058902A5 (https=)
US20220096652A1 (en) Acetal-based cleavable linkers
JP2016530254A5 (https=)
JP2004532217A5 (https=)
JP2017506262A (ja) タンパク質の選択的還元
WO2021068890A1 (zh) 溶酶体靶向的抗体-药物偶联物及其应用
JP2007527421A5 (https=)
BRPI0314831B1 (pt) composições farmacêuticas e composição de lipossoma peg compreendendo um conjugado, seus métodos de produção, kit e usos terapêuticos das ditas composições
RU2019129839A (ru) Производные майтанзиноида с саморасщепляющимися пептидными линкерами и их конъюгаты
JP7057391B2 (ja) タンパク薬物複合体で使用するためのリンカーに関連する材料および方法
JP7706668B2 (ja) 抗体-薬物コンジュゲート及びそれらの使用